section name header

Pronunciation

DES-ven-la-FAX-een

Classifications

Therapeutic Classification: antidepressants

Pharmacologic Classification: selective serotonin and norepinephrine reuptake inhibitors-SSNRIs

Indications

BEERS REMS


Action

  • Inhibits serotonin and norepinephrine reuptake in the CNS.
Therapeutic effects:
  • Decrease in depressive symptomatology, with fewer relapses/recurrences.

Pharmacokinetics

Absorption: 80% absorbed following oral administration.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: 55% metabolized by the liver, 45% excreted unchanged in urine.

Half-Life: 10 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown7.5 hr24 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension

Derm: sweating, ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS

EENT: intraocular pressure, mydriasis

Endo: SIADH

F and E: hyponatremia

GI: appetite, constipation, nausea, PANCREATITIS

GU: libido, delayed/absent orgasm, ejaculatory delay/failure, erectile dysfunction

Hemat: BLEEDING

Metab: hyperlipidemia

Neuro: anxiety, dizziness, drowsiness, insomnia, headache, NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES, SUICIDAL THOUGHTS, teeth grinding, vertigo

Resp: eosinophilic pneumonia, interstitial lung disease

Misc: discontinuation syndrome, SEROTONIN SYNDROME

Interactions

Drug-drug:

Route/Dosage

Hepatic Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Khedezla, Pristiq

Code

NDC Code